AU2000241348A1 - Amorphous torasemide modification - Google Patents

Amorphous torasemide modification

Info

Publication number: AU2000241348A1
Authority: AU; Australia
Prior art keywords: torasemide; amorphous; modification; torasemide modification; preparation
Prior art date: 2000-03-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2000241348A

Other languages

English (en)

Inventor

Aleksandar Danilovski

Miljenko Dumic

Darko Filic

Bozena Klepic

Marijan Tudja

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pliva Farmaceutika dd

Original Assignee

Pliva Farmaceutika dd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-20

Filing date

2000-05-02

Publication date

2001-10-03

2000-05-02 Application filed by Pliva Farmaceutika dd filed Critical Pliva Farmaceutika dd

2001-10-03 Publication of AU2000241348A1 publication Critical patent/AU2000241348A1/en

Status Abandoned legal-status Critical Current

Links

NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 title claims description 96
230000004048 modification Effects 0.000 title claims description 96
238000012986 modification Methods 0.000 title claims description 96
229960005461 torasemide Drugs 0.000 title claims description 94
239000000243 solution Substances 0.000 claims description 37
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
238000000034 method Methods 0.000 claims description 33
230000008569 process Effects 0.000 claims description 30
238000002360 preparation method Methods 0.000 claims description 23
239000013078 crystal Substances 0.000 claims description 21
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 20
238000004108 freeze drying Methods 0.000 claims description 20
239000000843 powder Substances 0.000 claims description 11
239000003795 chemical substances by application Substances 0.000 claims description 9
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 8
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 8
235000011114 ammonium hydroxide Nutrition 0.000 claims description 8
239000000203 mixture Substances 0.000 claims description 7
206010006451 bronchitis Diseases 0.000 claims description 6
239000002934 diuretic Substances 0.000 claims description 6
230000001882 diuretic effect Effects 0.000 claims description 6
208000028867 ischemia Diseases 0.000 claims description 6
229920002678 cellulose Polymers 0.000 claims description 4
239000001913 cellulose Substances 0.000 claims description 4
235000010980 cellulose Nutrition 0.000 claims description 4
206010002383 Angina Pectoris Diseases 0.000 claims description 3
208000012904 Bartter disease Diseases 0.000 claims description 3
208000010062 Bartter syndrome Diseases 0.000 claims description 3
206010048962 Brain oedema Diseases 0.000 claims description 3
206010006458 Bronchitis chronic Diseases 0.000 claims description 3
206010010254 Concussion Diseases 0.000 claims description 3
208000016998 Conn syndrome Diseases 0.000 claims description 3
208000010412 Glaucoma Diseases 0.000 claims description 3
206010020772 Hypertension Diseases 0.000 claims description 3
206010027476 Metastases Diseases 0.000 claims description 3
206010028980 Neoplasm Diseases 0.000 claims description 3
206010037423 Pulmonary oedema Diseases 0.000 claims description 3
206010039808 Secondary aldosteronism Diseases 0.000 claims description 3
208000007536 Thrombosis Diseases 0.000 claims description 3
230000005856 abnormality Effects 0.000 claims description 3
238000010521 absorption reaction Methods 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 3
230000001154 acute effect Effects 0.000 claims description 3
239000000654 additive Substances 0.000 claims description 3
239000013566 allergen Substances 0.000 claims description 3
208000006673 asthma Diseases 0.000 claims description 3
210000004556 brain Anatomy 0.000 claims description 3
208000006752 brain edema Diseases 0.000 claims description 3
208000007451 chronic bronchitis Diseases 0.000 claims description 3
230000009514 concussion Effects 0.000 claims description 3
230000003247 decreasing effect Effects 0.000 claims description 3
230000001037 epileptic effect Effects 0.000 claims description 3
210000005003 heart tissue Anatomy 0.000 claims description 3
208000015181 infectious disease Diseases 0.000 claims description 3
208000014674 injury Diseases 0.000 claims description 3
230000004410 intraocular pressure Effects 0.000 claims description 3
230000002503 metabolic effect Effects 0.000 claims description 3
208000013846 primary aldosteronism Diseases 0.000 claims description 3
208000005333 pulmonary edema Diseases 0.000 claims description 3
230000000451 tissue damage Effects 0.000 claims description 3
231100000827 tissue damage Toxicity 0.000 claims description 3
230000008733 trauma Effects 0.000 claims description 3
229920000881 Modified starch Polymers 0.000 claims description 2
229920002472 Starch Polymers 0.000 claims description 2
230000000181 anti-adherent effect Effects 0.000 claims description 2
239000002775 capsule Substances 0.000 claims description 2
238000002347 injection Methods 0.000 claims description 2
239000007924 injection Substances 0.000 claims description 2
235000019426 modified starch Nutrition 0.000 claims description 2
239000002994 raw material Substances 0.000 claims description 2
235000019698 starch Nutrition 0.000 claims description 2
239000008107 starch Substances 0.000 claims description 2
235000000346 sugar Nutrition 0.000 claims description 2
238000002844 melting Methods 0.000 description 23
230000008018 melting Effects 0.000 description 23
238000002329 infrared spectrum Methods 0.000 description 21
238000000354 decomposition reaction Methods 0.000 description 11
238000002955 isolation Methods 0.000 description 9
238000004090 dissolution Methods 0.000 description 8
239000003814 drug Substances 0.000 description 7
229910021529 ammonia Inorganic materials 0.000 description 6
238000001816 cooling Methods 0.000 description 5
238000001914 filtration Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
238000000113 differential scanning calorimetry Methods 0.000 description 4
239000007787 solid Substances 0.000 description 4
230000009471 action Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
238000004566 IR spectroscopy Methods 0.000 description 2
238000002441 X-ray diffraction Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 1
YAXMCEWRTZAGIM-DSTWUDMISA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-26-[(E)-(4-cyclopentylpiperazin-1-yl)iminomethyl]-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate hydrochloride Chemical compound Cl.CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C YAXMCEWRTZAGIM-DSTWUDMISA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
IIOPLILENRZKRV-UHFFFAOYSA-N azosemide Chemical compound C=1C=CSC=1CNC=1C=C(Cl)C(S(=O)(=O)N)=CC=1C1=NN=N[N]1 IIOPLILENRZKRV-UHFFFAOYSA-N 0.000 description 1
229960004988 azosemide Drugs 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
229960004064 bumetanide Drugs 0.000 description 1
MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012822 chemical development Methods 0.000 description 1
238000001938 differential scanning calorimetry curve Methods 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
229960003883 furosemide Drugs 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000000227 grinding Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000009878 intermolecular interaction Effects 0.000 description 1
230000008863 intramolecular interaction Effects 0.000 description 1
229960004130 itraconazole Drugs 0.000 description 1
239000002171 loop diuretic Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000003801 milling Methods 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229960001085 piretanide Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000013341 scale-up Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003860 storage Methods 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000001757 thermogravimetry curve Methods 0.000 description 1
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
229960001641 troglitazone Drugs 0.000 description 1
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
238000002211 ultraviolet spectrum Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Otolaryngology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Materials For Medical Uses (AREA)
Enzymes And Modification Thereof (AREA)
Medicinal Preparation (AREA)

AU2000241348A 2000-03-20 2000-05-02 Amorphous torasemide modification Abandoned AU2000241348A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
HRP20000162A		2000-03-20
HR20000162A HRP20000162B1 (en)	2000-03-20	2000-03-20	Amorphous torasemide modification
PCT/HR2000/000011 WO2001070694A1 (en)	2000-03-20	2000-05-02	Amorphous torasemide modification

Publications (1)

Publication Number	Publication Date
AU2000241348A1 true AU2000241348A1 (en)	2001-10-03

Family

ID=10947070

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2000241348A Abandoned AU2000241348A1 (en)	2000-03-20	2000-05-02	Amorphous torasemide modification

Country Status (29)

Country	Link
US (1)	US6767917B1 (is)
EP (1)	EP1272470B1 (is)
JP (1)	JP2003528083A (is)
KR (1)	KR20020093847A (is)
CN (1)	CN1211368C (is)
AR (1)	AR023788A1 (is)
AT (1)	ATE256662T1 (is)
AU (1)	AU2000241348A1 (is)
BG (1)	BG107208A (is)
BR (1)	BR0017175A (is)
CA (1)	CA2401908A1 (is)
CZ (1)	CZ20023436A3 (is)
DE (1)	DE60007360T2 (is)
EA (1)	EA004950B1 (is)
EE (1)	EE200200534A (is)
ES (1)	ES2213006T3 (is)
GE (1)	GEP20043300B (is)
HR (1)	HRP20000162B1 (is)
HU (1)	HUP0300596A3 (is)
IL (1)	IL151801A0 (is)
IS (1)	IS6551A (is)
MX (1)	MXPA02009210A (is)
NO (1)	NO20024464L (is)
PL (1)	PL357154A1 (is)
PT (1)	PT1272470E (is)
SK (1)	SK15092002A3 (is)
WO (1)	WO2001070694A1 (is)
YU (1)	YU70502A (is)
ZA (1)	ZA200208309B (is)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI20816A (sl) *	1999-08-11	2002-08-31	Teva Pharmaceutical Industries Ltd.	Polimorfi torsemid-a
IN192178B (is) *	2001-08-03	2004-03-06	Ranbaxy Lab
EP1668008A4 (en)	2003-08-28	2009-02-25	Nitromed Inc	NITROSED AND NITROSYLATED DIETETIC COMPOUNDS, COMPOSITIONS AND APPLICATION METHODS
AU2006216665A1 (en)	2005-02-24	2006-08-31	Nicox S.A.	Nitric oxide enhancing diuretic compounds, compositions and methods of use
CN100421662C (zh) *	2005-11-08	2008-10-01	周卓和	托拉塞米分散片及其制备方法和应用
CN104370805B (zh) *	2013-08-13	2016-09-07	天津汉瑞药业有限公司	托拉塞米化合物
CN105949115A (zh) *	2016-05-26	2016-09-21	南京正科医药股份有限公司	一种新晶型托拉塞米
CN115417810B (zh) *	2022-09-22	2023-10-10	南京正科医药股份有限公司	一种托拉塞米晶型ⅰ的精制方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1477664A (en)	1974-04-17	1977-06-22	Christiaens Sa A	Pyridine derivatives
DE3529529A1 (de) *	1985-08-17	1987-02-19	Boehringer Mannheim Gmbh	Verfahren zur herstellung einer stabilen modifikation von torasemid
GB8816620D0 (en)	1988-07-13	1988-08-17	Lepetit Spa	Rifapentine hydrohalides
ES2150105T3 (es)	1995-02-22	2000-11-16	Aventis Pharma Ltd	Piretanida amorfa, polimorfos de piretanida, proceso para su preparacion y su uso.
IN182496B (is)	1996-02-20	1999-04-17	Reddy Research Foundation
HRP980532B1 (en)	1998-10-02	2005-06-30	Pliva	Novel crystalline torasemide modification
US5914336A (en) *	1998-06-02	1999-06-22	Boehringer Mannheim Gmbh	Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
SI20816A (sl)	1999-08-11	2002-08-31	Teva Pharmaceutical Industries Ltd.	Polimorfi torsemid-a

2000
- 2000-03-20 HR HR20000162A patent/HRP20000162B1/xx not_active IP Right Cessation
- 2000-04-28 AR ARP000102019A patent/AR023788A1/es unknown
- 2000-05-02 BR BR0017175-1A patent/BR0017175A/pt not_active IP Right Cessation
- 2000-05-02 JP JP2001568906A patent/JP2003528083A/ja active Pending
- 2000-05-02 AT AT00920938T patent/ATE256662T1/de not_active IP Right Cessation
- 2000-05-02 MX MXPA02009210A patent/MXPA02009210A/es unknown
- 2000-05-02 EP EP00920938A patent/EP1272470B1/en not_active Expired - Lifetime
- 2000-05-02 CA CA002401908A patent/CA2401908A1/en not_active Abandoned
- 2000-05-02 SK SK1509-2002A patent/SK15092002A3/sk unknown
- 2000-05-02 ES ES00920938T patent/ES2213006T3/es not_active Expired - Lifetime
- 2000-05-02 US US10/239,024 patent/US6767917B1/en not_active Expired - Fee Related
- 2000-05-02 GE GE4937A patent/GEP20043300B/en unknown
- 2000-05-02 PT PT00920938T patent/PT1272470E/pt unknown
- 2000-05-02 WO PCT/HR2000/000011 patent/WO2001070694A1/en not_active Ceased
- 2000-05-02 EA EA200201003A patent/EA004950B1/ru not_active IP Right Cessation
- 2000-05-02 DE DE60007360T patent/DE60007360T2/de not_active Expired - Fee Related
- 2000-05-02 AU AU2000241348A patent/AU2000241348A1/en not_active Abandoned
- 2000-05-02 CN CNB008194319A patent/CN1211368C/zh not_active Expired - Fee Related
- 2000-05-02 YU YU70502A patent/YU70502A/sh unknown
- 2000-05-02 IL IL15180100A patent/IL151801A0/xx unknown
- 2000-05-02 KR KR1020027012411A patent/KR20020093847A/ko not_active Withdrawn
- 2000-05-02 PL PL00357154A patent/PL357154A1/xx not_active Application Discontinuation
- 2000-05-02 HU HU0300596A patent/HUP0300596A3/hu unknown
- 2000-05-02 EE EEP200200534A patent/EE200200534A/xx unknown
- 2000-05-02 CZ CZ20023436A patent/CZ20023436A3/cs unknown
2002
- 2002-09-17 IS IS6551A patent/IS6551A/is unknown
- 2002-09-18 NO NO20024464A patent/NO20024464L/no not_active Application Discontinuation
- 2002-10-15 ZA ZA200208309A patent/ZA200208309B/en unknown
- 2002-10-21 BG BG107208A patent/BG107208A/xx unknown

Also Published As

Publication number	Publication date
AR023788A1 (es)	2002-09-04
PL357154A1 (en)	2004-07-12
CZ20023436A3 (cs)	2003-03-12
HRP20000162B1 (en)	2004-06-30
CA2401908A1 (en)	2001-09-27
GEP20043300B (en)	2004-02-10
MXPA02009210A (es)	2004-09-06
NO20024464L (no)	2002-09-20
JP2003528083A (ja)	2003-09-24
US6767917B1 (en)	2004-07-27
EE200200534A (et)	2004-04-15
CN1452613A (zh)	2003-10-29
IL151801A0 (en)	2003-04-10
WO2001070694A1 (en)	2001-09-27
YU70502A (sh)	2006-01-16
HRP20000162A2 (en)	2001-12-31
DE60007360D1 (de)	2004-01-29
ATE256662T1 (de)	2004-01-15
DE60007360T2 (de)	2004-10-07
EP1272470A1 (en)	2003-01-08
EP1272470B1 (en)	2003-12-17
BR0017175A (pt)	2002-12-10
NO20024464D0 (no)	2002-09-18
EA004950B1 (ru)	2004-10-28
BG107208A (bg)	2003-07-31
SK15092002A3 (sk)	2003-05-02
ZA200208309B (en)	2003-10-15
EA200201003A1 (ru)	2003-02-27
HUP0300596A2 (hu)	2003-07-28
WO2001070694A8 (en)	2002-03-21
ES2213006T3 (es)	2004-08-16
IS6551A (is)	2002-09-17
KR20020093847A (ko)	2002-12-16
CN1211368C (zh)	2005-07-20
HUP0300596A3 (en)	2005-08-29
PT1272470E (pt)	2004-05-31

Publication	Publication Date	Title
US20070276015A1 (en)	2007-11-29	Crystal modification of torasemide
US20070238759A1 (en)	2007-10-11	Novel Polymorph V of Torasemide
DK1755596T5 (en)	2016-05-23	Process for the preparation of atazanavirbisulfat and novel forms
EP1272470B1 (en)	2003-12-17	Amorphous torasemide modification
HK1058203A (en)	2004-05-07	Amorphous torasemide modification
MXPA01003325A (en)	2002-03-05	New crystal modification iii of torasemide